COST MINIMIZATION ANALYSIS OF ORAL VALGANCICLOVIR VERSUS INTRAVENOUS AND ORAL GANCICLOVIR IN THE PREVENTION OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN SOLID ORGAN TRANSPLANT RECIPIENTS | Publicación